In addition, long-term therapy with different drugs regulating transcription factors such as FXR [160,161], peroxisome proliferator-activated receptors [113], and pregnane X receptor [114] have shown beneficial effects in NASH. The gene discussed is NR1I2; the disease is metabolic dysfunction-associated steatohepatitis.